US-based Thermo Fisher Scientific has expanded its LABScreen™ Single Antigen ExPlex Portfolio with the introduction of LABScreen Single Antigen HLA Class II ExPlex – Group 2. The new panel extends HLA-DQ coverage, enabling more comprehensive
Available now in the European Union under IVDR, the extended ExPlex panel can be combined in a single well with LABScreen Single Antigen assays — the established standard for HLA antibody detection — without requiring additional
The detection and characterisation of human leukocyte antigen (HLA) antibodies are central to assessing immunological risk in transplantation. While conventional HLA antibody testing has traditionally focused on antigen-level reactivity, increasing attention has shifted toward epitope- and eplet-based analysis as a more refined approach to understanding alloimmune responses.
“HLA-DQ antibodies have become an area of increasing clinical focus, with growing evidence linking them to transplant rejection,” said Dave Lowe, senior director, research and development, transplant diagnostics, Thermo Fisher Scientific. “By expanding HLA-DQ coverage within an existing workflow, laboratories can support better-informed matching decisions before transplant and more comprehensive monitoring after, where earlier detection of donor-specific antibodies can make a meaningful difference for patients.”
